iZafe Group AB Series B - Asset Resilience Ratio
iZafe Group AB Series B (IZAFE-B) has an Asset Resilience Ratio of 4.69% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check IZAFE-B PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how iZafe Group AB Series B's Asset Resilience Ratio has changed over time. See iZafe Group AB Series B (IZAFE-B) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down iZafe Group AB Series B's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IZAFE-B market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr1.67 Million | 4.69% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr1.67 Million | 4.69% |
Asset Resilience Insights
- Limited Liquidity: iZafe Group AB Series B maintains only 4.69% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
iZafe Group AB Series B Industry Peers by Asset Resilience Ratio
Compare iZafe Group AB Series B's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087 |
Medical Instruments & Supplies | 9.87% |
|
Andon Health Co Ltd
SHE:002432 |
Medical Instruments & Supplies | 18.11% |
|
Pegavision
TW:6491 |
Medical Instruments & Supplies | 17.14% |
|
Tarsons Products Limited
NSE:TARSONS |
Medical Instruments & Supplies | 0.47% |
|
SciVision Biotech Inc
TW:1786 |
Medical Instruments & Supplies | 7.81% |
|
Nyxoah
BR:NYXH |
Medical Instruments & Supplies | 12.40% |
|
I.Ceram SA
PA:ALICR |
Medical Instruments & Supplies | -1.61% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
Annual Asset Resilience Ratio for iZafe Group AB Series B (2016–2025)
The table below shows the annual Asset Resilience Ratio data for iZafe Group AB Series B.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.69% | Skr1.67 Million ≈ $180.04K |
Skr35.63 Million ≈ $3.83 Million |
-4.18pp |
| 2024-12-31 | 8.87% | Skr2.15 Million ≈ $231.37K |
Skr24.23 Million ≈ $2.61 Million |
-7.98pp |
| 2023-12-31 | 16.85% | Skr5.83 Million ≈ $627.83K |
Skr34.61 Million ≈ $3.73 Million |
+13.50pp |
| 2022-12-31 | 3.35% | Skr1.70 Million ≈ $183.05K |
Skr50.70 Million ≈ $5.46 Million |
-35.31pp |
| 2021-12-31 | 38.67% | Skr18.73 Million ≈ $2.02 Million |
Skr48.43 Million ≈ $5.21 Million |
+31.40pp |
| 2020-12-31 | 7.26% | Skr2.55 Million ≈ $274.21K |
Skr35.08 Million ≈ $3.78 Million |
-3.14pp |
| 2019-12-31 | 10.41% | Skr7.47 Million ≈ $803.57K |
Skr71.75 Million ≈ $7.72 Million |
+7.64pp |
| 2018-12-31 | 2.77% | Skr1.21 Million ≈ $129.89K |
Skr43.58 Million ≈ $4.69 Million |
-23.36pp |
| 2017-12-31 | 26.13% | Skr3.58 Million ≈ $385.70K |
Skr13.71 Million ≈ $1.48 Million |
-17.89pp |
| 2016-12-31 | 44.03% | Skr3.56 Million ≈ $383.44K |
Skr8.09 Million ≈ $870.88K |
-- |
About iZafe Group AB Series B
iZafe Group AB (publ), a medical technology company, engages in the research, development, and marketing of digital medical solutions and services for safer drug management at home. The company provides Dosell, an automated medication dispenser that handles medication pouches, smart pillboxes, facilitates and enables independent medication, and reminds and alerts in the scheduled doses. It also o… Read more